The Role of Nef and Cyclophilin A in HIV-1 Disassembly
Project Number1R21AI060370-01A1
Contact PI/Project LeaderPOWELL, MICHAEL D
Awardee OrganizationMOREHOUSE SCHOOL OF MEDICINE
Description
Abstract Text
DESCRIPTION (provided by applicant): The development of new HIV-1 antivirals is dependent on our understanding of the individual steps in viral replication. Perhaps the least understood aspect of HIV-1 replication is the process of disassembly. Our preliminary data suggest that the viral protein Nef and the cellular factor cyclophilin A (CyPA) are involved in some aspect of disassembly. We have shown that HIV-1 viruses that have their own nef deleted and replaced by HIV-2 or SIV Nef "in trans" become resistant to cyclosporine A treatment. This suggests some interdependence between Nef and CyPA. It has been previously shown that Nef and CyPA can directly interact. We have confirmed this result in our own lab using Far Western blots and SELDI mass spectrometry. We consider whether the interactions between Nef and CyPA and their potential interactions with CA in the viral core are important for replication. Our hypothesis is: that interaction between Nef, CyPA and CA are important for enhancement of viral infectivity. Our approach is summarized in three specific aims: 1. Characterize the ability of HIV-2 and SIV Nef to induce cyclophilin A independence in HIV-1 virions using a multi-round infectivity assay. 2. Determine if the interaction between HIV-1 Nef and CyPA is relevant to enhancement of infectivity. 3. Determine if the HIV-1, HIV-2 or SIV Nef proteins can directly or indirectly bind to CA protein. A better understanding of the relationship between Nef and CyPA will provide critical details about this poorly characterized step in replication, which could provide an attractive new target for antiviral therapy.
National Institute of Allergy and Infectious Diseases
CFDA Code
856
DUNS Number
102005451
UEI
X5S7PNXMJMC7
Project Start Date
01-June-2004
Project End Date
31-May-2006
Budget Start Date
01-June-2004
Budget End Date
31-May-2005
Project Funding Information for 2004
Total Funding
$173,300
Direct Costs
$125,000
Indirect Costs
$48,300
Year
Funding IC
FY Total Cost by IC
2004
National Institute of Allergy and Infectious Diseases
$173,300
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 1R21AI060370-01A1
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 1R21AI060370-01A1
Patents
No Patents information available for 1R21AI060370-01A1
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 1R21AI060370-01A1
Clinical Studies
No Clinical Studies information available for 1R21AI060370-01A1
News and More
Related News Releases
No news release information available for 1R21AI060370-01A1
History
No Historical information available for 1R21AI060370-01A1
Similar Projects
No Similar Projects information available for 1R21AI060370-01A1